Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rintatolimod + interferon alfa-2b
- Development stage
- Unknown
- Lead developer
- AIM ImmunoTech
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
rintatolimod + interferon alfa-2b is an investigational combination immunotherapy regimen being evaluated for the treatment of COVID-19 in cancer patients. Rintatolimod (brand name Ampligen) is a synthetic double-stranded RNA (dsRNA) molecule that acts as a Toll-like receptor 3 (TLR3) agonist, mimicking viral infection to stimulate the innate immune system and activate the interferon pathway. Interferon alfa-2b is a recombinant Type I interferon that provides direct antiviral activity and enhances the immune response. Developed by AIM ImmunoTech in collaboration with Roswell Park Comprehensive Cancer Center, this combination aims to promote viral clearance of SARS-CoV-2 by depriving the virus of its ability to replicate. The regimen was authorized for Phase 1/2a clinical trials in May 2020 specifically for cancer patients with mild to moderate symptomatic COVID-19, representing a repurposing of an experimental cancer therapy originally developed for solid tumors.
- Brand names
- AmpligenIntron A
- Other names
- rintatolimod and interferon alfa-2b regimenrintatolimod and IFN alpha regimen
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on rintatolimod + interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rintatolimod + interferon alfa-2b.